For which of these patients would you give the 23-valent pneumoccocal vaccine?
Which of the following should get the 23-valent pneumoccocal (Pneumovax) vaccine per the Advisory Committee on Immunization Practices (ACIP) guidelines?
AstraZeneca’s Investigational COVID-19 Prevention Drug Reduces Risk of Infection in Immunocompromised Persons
Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Moderna Will Have to Wait for FDA Approval of Investigational RSV Vaccine
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
Primary Viewpoints Episode 11: AAFP President-elect Discusses Greatest Concerns about Upcoming Flu Season
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with incoming AAFP president Sterling Ransone, MD.
COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone: Daily Dose
Your daily dose of the clinical news you may have missed.
Merck's 21-Valent Pneumococcal Vaccine Delivers More Positive Phase 3 Data in Advance of 6-17-2024 PDUFA Date
In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.